The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Vertex Pharmaceuticals Inc

Nasdaq: VRTX
Last

(U.S.) $93.89

Today's change+0.68 +0.73%
Updated July 22 4:00 PM EDT. Delayed by at least 15 minutes.
 

Vertex Pharmaceuticals Inc

Nasdaq: VRTX
Last

(U.S.) $93.89

Today's change+0.68 +0.73%
Updated July 22 4:00 PM EDT. Delayed by at least 15 minutes.

Vertex Pharmaceuticals Inc Hits New 20-day High

Vertex Pharmaceuticals Inc closed up Friday by (U.S.)$0.68 or 0.73% to (U.S.)$93.89 and setting a new 20-day high. Over the last five days, shares have gained 4.08%, but are down 25.38% for the last year to date. Shares have underperformed the S&P 500 by 31.22% during the last year.

Key company metrics

  • Open(U.S.) $93.63
  • Previous close(U.S.) $93.21
  • High(U.S.) $94.29
  • Low(U.S.) $92.70
  • Bid / Ask(U.S.) $71.12 / (U.S.) $99.90
  • YTD % change-25.38%
  • Volume1,235,510
  • Average volume (10-day)1,322,206
  • Average volume (1-month)1,457,015
  • Average volume (3-month)1,852,406
  • 52-week range(U.S.) $75.90 to (U.S.) $143.45
  • Beta0.55
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forward91.64×
  • Forward PEG1.79×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.65
Updated July 22 4:00 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.24%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2016Q4/2015Q3/2015Q2/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015
Revenue398418310166
Total other revenue--------
Total revenue398418310166
Gross profit348356280151
Total cost of revenue50623015
Total operating expense412472380337
Selling / general / administrative1059710094
Research & development256310246224
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)1222
Other operating expenses, total1121
Operating income-14-54-70-171
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-31-76-92-191
Income after tax-36-75-94-221
Income tax, total5-1130
Net income-42-74-95-189
Total adjustments to net income--------
Net income before extra. items-42-74-95-189
Minority interest-61-132
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-42-74-95-189
Inc. avail. to common incl. extra. items-42-74-95-189
Diluted net income-42-74-95-189
Dilution adjustment--------
Diluted weighted average shares244243242241
Diluted EPS excluding extraordinary itemsvalue per share-0.17-0.30-0.39-0.78
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share-0.17-0.30-0.39-0.78